Publications
Anantharaman A, Friedlander TW. The double-edged sword of ADT: emerging evidence of cardiovascular, pulmonary, and renal risks. Oncology (Williston Park, N.Y.). 2015. PMID: 25592211
Roff SR, Sanou MP, Rathore MH, Levy JA, Yamamoto JK. Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects. Human vaccines & immunotherapeutics. 2015. PMID: 25844718
Sarah Keck, Melanie Majure, Hope S. Rugo. Management of Metastatic Breast Cancer. Breast disease. 2015. PMID:
Tempero M. Meet the New JNCCN! Journal of the National Comprehensive Cancer Network : JNCCN. 2015. PMID: 25583762
Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015. PMID: 25993177
Hrustanovic G, Bivona TG. RAS-MAPK in ALK targeted therapy resistance. Cell cycle (Georgetown, Tex.). 2015. PMID: 26654768
Flaherty KT, Wargo JA, Bivona TG. YAP in MAPK pathway targeted therapy resistance. Cell cycle (Georgetown, Tex.). 2015. PMID: 26036142
Park J, Thomas S, Munster PN. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics. 2015. PMID: 26111034
Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2014. PMID: 25550361
Shahi P, Slorach EM, Wang CY, Chou J, Lu A, Ruderisch A, Werb Z. The Transcriptional Repressor ZNF503/Zeppo2 Promotes Mammary Epithelial Cell Proliferation and Enhances Cell Invasion. The Journal of biological chemistry. 2014. PMID: 25538248
Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014. PMID: 25534386
Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY, Smith CC, Shah NP, Shokat KM. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. eLife. 2014. PMID: 25531068
Komanduri KV, Veys P. Selected reviews from the 2015 BMT tandem meetings. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014. PMID: 25534537
Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS, Translational Breast Cancer Research Consortium. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. PMID: 25524311
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2014. PMID: 25530442
Cushman SM, Jiang C, Hatch AJ, Shterev I, Sibley AB, Niedzwiecki D, Venook AP, Owzar K, Hurwitz HI, Nixon AB. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. PMID: 25520391
Rajan N, Elliott RJ, Smith A, Sinclair N, Swift S, Lord CJ, Ashworth A. The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling. Oncotarget. 2014. PMID: 25565632
Shen J, Wei J, Guan W, Wang H, Ding Y, Qian X, Yu L, Zou Z, Xie L, Costa C, Bivona T, Rosell R, Liu B. Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. Journal of translational medicine. 2014. PMID: 25496700
Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakhshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer discovery. 2014. PMID: 25501949
Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Clinical genitourinary cancer. 2014. PMID: 25557266